Switch to:
More From Other Websites
Exclusive - 'Back to normal' for AstraZeneca CEO, despite Pfizer rumours Sep 02 2014
Weaker healthcare stocks weigh on European equities Sep 02 2014
Exclusive: 'Back to normal' for AstraZeneca CEO, despite Pfizer rumors Sep 02 2014
1:15 am Pfizer and Bristol-Myers (BMY) reports secondary analysis... Sep 02 2014
Public Pension Funds Stay Mum on Corporate Expats Sep 01 2014
Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress:... Aug 30 2014
Pfizer's C. Difficile Vaccine Gets Fast Track Status Aug 29 2014
Partnering With Big Pharma, Parexel Hits Its Stride Aug 29 2014
Protalix/Pfizer's Elelyso Approved in Pediatric Patients Aug 29 2014
Investors Bet AstraZeneca Megamerger Could Live Again Aug 29 2014
Dow 30 Stock Roundup: UTX Reiterates Guidance, BA Wins $8.8B Order Aug 29 2014
InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN® Aug 29 2014
AstraZeneca shares rise on takeover and drug hopes Aug 29 2014
Fed Chair Yellen's assets up 8% during 2013 Aug 28 2014
AstraZeneca Pops on Possibility of Another Pfizer Bid Aug 28 2014
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™... Aug 28 2014
[$$] Pfizer Vaccine Candidate Gets Fast Track Aug 28 2014
Pfizer’s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug... Aug 28 2014
Your first trade for Thursday Aug 27 2014
Pfizer and Merck Collaborate to Develop Lung Cancer Therapy Aug 27 2014

Add Notes, Comments or Ask Questions

User Comments

ReplySEENSCO - 2 months ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial